4-chlorobutyl (2E,4E)-hexa-2,4-dienoate | 88973-66-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-chlorobutyl (2E,4E)-hexa-2,4-dienoate
• CAS: 88973-66-4
• 化学式: C₁₀H₁₅ClO₂
• 分子量: 202.681
• InChiKey: AKZLUCNEUMQGLC-AOGGBPEJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chlorobutyl (2E,4E)-hexa-2,4-dienoate 以 丙酮 、 苯 为溶剂， 反应 5.0h， 生成 4-(1-methylpiperidin-1-ium-1-yl)butyl (2E,4E)-hexa-2,4-dienoate;iodide
  参考文献：
  名称：

  Le Baut; Sparfel; Clairc, European Journal of Medicinal Chemistry, 1983, vol. 18, # 5, p. 441 - 445

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯丁醇 、 山梨酸氯化物 以60%的产率得到4-chlorobutyl (2E,4E)-hexa-2,4-dienoate
  参考文献：
  名称：

  Le Baut; Sparfel; Clairc, European Journal of Medicinal Chemistry, 1983, vol. 18, # 5, p. 441 - 445

  摘要：

  DOI：

文献信息

• Treatment of skin disorders by topical administration of VEGF inhibitors
  申请人：AMD THERAPEUTICS LLC

  公开号：US10709702B2

  公开（公告）日：2020-07-14

  Topical administration of VEGF inhibitors such as, without limitation, rifamycin compounds are useful for treating skin disorders such as treating and/or reducing scars such as hypertrophic scars, and useful for treating acne and underlying acne symptoms such as skin redness.

  局部使用血管内皮生长因子抑制剂（如但不限于利福霉素化合物）可用于治疗皮肤疾病，如治疗和/或减少疤痕（如增生性疤痕），还可用于治疗痤疮和潜在的痤疮症状（如皮肤发红）。
• LE, BAUT, G.;SPARFEL, L.;CLAIRC, C.;FLOCH, R.;BENAZET, F.;LACROIX, L.;LER+, EUR. J. MED. CHEM., 1983, 18, N 5, 441-445
  作者：LE, BAUT, G.、SPARFEL, L.、CLAIRC, C.、FLOCH, R.、BENAZET, F.、LACROIX, L.、LER+

  DOI：——

  日期：——
• OPHTHALMIC COMPOSITIONS OF RIFAMYCINS AND USES THEREOF
  申请人：Serizawa Hiroaki

  公开号：US20170202850A1

  公开（公告）日：2017-07-20

  Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations. This invention relates generally to pharmaceutical compositions or formulations suitable for administration to an eye. In some aspects, this invention relates to ophthalmic pharmaceutical compositions or formulations comprising one or more rifamycin compounds selected from the group consisting of rifampicin, rifabutin, rifapentine. In one aspect, the invention relates to methods of treating an ocular disease, disorder or condition comprising administering to a patient in need thereof an ophthalmic composition comprising an effective amount of a rifamycin compound selected from the group consisting of rifampicin, rifabutin, rifapentine, and rifaximin.
• TREATMENT OF SKIN DISORDERS BY TOPICAL ADMINISTRATION OF VEGF INHIBITORS
  申请人：AMD THERAPEUTICS LLC

  公开号：US20180289701A1

  公开（公告）日：2018-10-11

  Topical administration of VEGF inhibitors such as, without limitation, rifamycin compounds are useful for treating skin disorders such as treating and/or reducing scars such as hypertrophic scars, and useful for treating acne and underlying acne symptoms such as skin redness.
• [EN] OPHTHALMIC COMPOSITIONS OF RIFAMYCINS AND USES THEREOF<br/>[FR] COMPOSITIONS OPHTALMIQUES DE RIFAMYCINES ET LEURS UTILISATIONS
  申请人：SERIZAWA HIROAKI

  公开号：WO2016014437A1

  公开（公告）日：2016-01-28

  Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations. This invention relates generally to pharmaceutical compositions or formulations suitable for administration to an eye. In some aspects, this invention relates to ophthalmic pharmaceutical compositions or formulations comprising one or more rifamycin compounds selected from the group consisting of rifampicin, rifabutin, rifapentine. In one aspect, the invention relates to methods of treating an ocular disease, disorder or condition comprising administering to a patient in need thereof an ophthalmic composition comprising an effective amount of a rifamycin compound selected from the group consisting of rifampicin, rifabutin, rifapentine, and rifaximin.